Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Judge Halts Alzheimer’s Drug Swap Until July

By Pharmaceutical Processing | December 16, 2014

ALBANY, N.Y. (AP) — A federal judge on Monday ordered Actavis to halt its plans to discontinue its widely used Alzheimer’s medication, allegedly in an effort to drive patients to a newer patented drug.

U.S. District Judge Robert Sweet told Dublin-based Actavis PLC to continue making the drug Namenda available for 30 days after generic alternatives become available on July 11 “in order to allow for an orderly transition.”

His injunction orders the company to inform doctors and pharmacists of the decision and tells Actavis not to impose any hurdles for filling prescriptions of the drug.

Actavis said it will appeal Monday’s ruling. The company said its new drug Namenda XR — taken once daily instead of twice — is better and demand is growing.

The ruling will have “no impact on its ability to continue focusing its resources on transitioning patients” to the new drug, Actavis said. It is “prepared to manage its business in a way that provides the least disruption in its ability to support the marketplace and minimize any financial impact.”

New York Attorney General Eric Schneiderman sought the court order. He alleged that Actavis and New York subsidiary Forest Laboratories violated anti-trust and state laws in an effort to avoid losses from cheaper generic alternatives coming out next year.

“Unfortunately, schemes to block competition, without considering the consequences to patients, are a growing trend in the health care industry,” Schneiderman said when he filed the lawsuit in September. His office is looking at other drugs and companies.

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE